5,312 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by Meiji Yasuda Asset Management Co Ltd.

Meiji Yasuda Asset Management Co Ltd. bought a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 5,312 shares of the company’s stock, valued at approximately $895,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Geneos Wealth Management Inc. increased its position in shares of Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares in the last quarter. DJE Kapital AG bought a new position in Neurocrine Biosciences in the 4th quarter valued at approximately $28,000. Basecamp Wealth Advisors LLC boosted its stake in Neurocrine Biosciences by 582.9% during the 1st quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock valued at $31,000 after purchasing an additional 204 shares during the last quarter. Cassaday & Co Wealth Management LLC purchased a new stake in Neurocrine Biosciences during the 1st quarter valued at $33,000. Finally, Meeder Asset Management Inc. increased its holdings in shares of Neurocrine Biosciences by 651.6% in the 4th quarter. Meeder Asset Management Inc. now owns 233 shares of the company’s stock worth $33,000 after purchasing an additional 202 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on NBIX shares. Citigroup boosted their price target on Neurocrine Biosciences from $246.00 to $249.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Truist Financial lifted their price objective on Neurocrine Biosciences from $200.00 to $213.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Needham & Company LLC boosted their target price on Neurocrine Biosciences from $200.00 to $204.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Wall Street Zen cut shares of Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research note on Sunday, August 9th. Finally, JPMorgan Chase & Co. raised their price target on shares of Neurocrine Biosciences from $177.00 to $185.00 and gave the company an “overweight” rating in a report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $200.86.

Insider Buying and Selling

In other Neurocrine Biosciences news, insider Julie Cooke sold 36,937 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $156.22, for a total transaction of $5,770,298.14. Following the completion of the sale, the insider owned 22,374 shares of the company’s stock, valued at approximately $3,495,266.28. The trade was a 62.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Darin Lippoldt sold 10,000 shares of the company’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $179.60, for a total value of $1,796,000.00. Following the completion of the sale, the insider owned 54,729 shares of the company’s stock, valued at approximately $9,829,328.40. The trade was a 15.45% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 116,636 shares of company stock worth $19,349,078 in the last quarter. Company insiders own 4.60% of the company’s stock.

Neurocrine Biosciences Trading Up 0.2%

Shares of NBIX stock opened at $153.37 on Wednesday. Neurocrine Biosciences, Inc. has a 12 month low of $122.14 and a 12 month high of $186.12. The stock has a market cap of $15.59 billion, a P/E ratio of 22.49, a P/E/G ratio of 0.72 and a beta of 0.39. The company has a 50 day simple moving average of $166.95 and a two-hundred day simple moving average of $149.17.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Friday, July 31st. The company reported $2.85 earnings per share for the quarter, topping the consensus estimate of $1.65 by $1.20. Neurocrine Biosciences had a net margin of 20.91% and a return on equity of 22.43%. The business had revenue of $959.00 million for the quarter, compared to analysts’ expectations of $891.16 million. During the same quarter last year, the company posted $1.65 EPS. The company’s revenue was up 39.5% compared to the same quarter last year. As a group, equities analysts forecast that Neurocrine Biosciences, Inc. will post 7.25 earnings per share for the current year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.